Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test

NCT05257434 · tracked via the Priya Life Science Japan tracker

Sponsor

Kochi University

Phase

Observational

Started

2019-01-01

Last updated

2022-02-25

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

inbody

inbody: Body fluid composition

Study summary

postoperative outcomes were evaluated by using inBody test

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * surgically treated patients Exclusion Criteria: * a body weight loss of \>10% during the 6 months before surgery; the presence of distant metastases; or seriously impaired function of vital organs because of respiratory, renal, or heart disease

Primary outcome measure(s)

long-term outcomes — 5year
overall survival rate

Trial sites (1)

Facility	City	Region	Status
Takehiro Okabayashi	Kochi	Japan	Recruiting

More Kochi University trials in Japan

Both Short- and Long-term Outcome Differences According to Patient Frailty Recruiting

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP Recruiting

Other trials for the same condition

Pan Tumor Rollover Study Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Recruiting

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) Active, not recruiting

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Active, not recruiting

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05257434 on ClinicalTrials.gov ↗ ← All trials in Japan